{
  "meta": {
    "timestamp": "2025-01-06T14:07:23.164307",
    "version": "1.0",
    "type": "search_analysis"
  },
  "companies": [
    {
      "company_name": "Nevro Corp",
      "symbol": "NVRO",
      "analysis": {
        "historical": {
          "risk_score": 65,
          "key_risks": [
            "Patent litigation and intellectual property risks",
            "Regulatory and reimbursement challenges",
            "Competitive pressures in the neuromodulation market",
            "Financial and market risks, including potential declines in market capitalization"
          ],
          "controversies": [
            "Delaware jury finding of patent infringement against Boston Scientific",
            "Settled IP litigation with Nalu Medical"
          ],
          "environmental_issues": [],
          "social_issues": [
            "Variability in reimbursement policies affecting patient access to treatments"
          ],
          "governance_issues": [
            "Legal disputes and potential financial penalties impacting corporate governance"
          ],
          "recommendation": "caution",
          "confidence_score": 80
        },
        "evidence": {
          "sources": [
            {
              "url": "",
              "title": "Nevro Corp. - Nevro Announces Update in Patent Litigation with Boston ...",
              "snippet": "Nevro Corp. (NYSE: NVRO), a global medical device company that provides innovative, evidence-based solutions for the treatment of chronic pain, today announced that a Delaware jury found that Nevro infringed two Boston Scientific patents (7,891,085 and 8,019,439) directed to ways of manufacturing spinal cord stimulation (SCS) leads, which Nevro obtains from a third-party supplier. Two other ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Nevro Corp Nevro Corp litigation history",
              "retrieved_at": "2025-01-06T21:06:53.765127+00:00",
              "published_date": null,
              "source_hash": "edb756ddb9ef9aca58b8793cf7e010b5"
            },
            {
              "url": "",
              "title": "Nevro Corp. v. Boston Scientific Corp., No. 18-2220 (Fed. Cir. 2020)",
              "snippet": "Nevro sued, alleging infringement of 18 claims across seven patents that are directed to high-frequency spinal cord stimulation therapy for inhibiting pain. Conventional spinal cord stimulation systems deliver electrical pulses to the spinal cord to generate sensations, such as tingling or paresthesia, that mask or otherwise alter the patient's pain. The claimed invention purportedly ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Nevro Corp Nevro Corp litigation history",
              "retrieved_at": "2025-01-06T21:06:53.765238+00:00",
              "published_date": null,
              "source_hash": "209465ffc0fabaa429bc5384c5ebb435"
            },
            {
              "url": "",
              "title": "Nevro Announces Settlement of IP Litigation with Nalu Medical",
              "snippet": "Nevro and Nalu Reached an Agreement to Dismiss Ongoing Litigation Premised on Nalu Medical No Longer Offering a High Frequency SCS Therapy Nevro Corp. (NYSE: NVRO), a global medical device company that provides innovative, evidence-based solutions for the treatment of chronic pain, today announced the settlement of its patent lawsuit with Nalu Medical. In February 2020, Nevro filed a patent ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Nevro Corp Nevro Corp litigation history",
              "retrieved_at": "2025-01-06T21:06:53.765253+00:00",
              "published_date": null,
              "source_hash": "f3217298ed3e4289b3bf97b5e4c66d0a"
            },
            {
              "url": "",
              "title": "NEVRO CORP v. BOSTON SCIENTIFIC CORPORATION (2020)",
              "snippet": "Nevro Corporation sued Boston Scientific Corporation and Boston Scientific Neuromodulation Corporation (collectively, Boston Scientific) in the Northern District of California, alleging infringement of eighteen claims across seven patents: U.S. Patent Nos. 8,359,102; 8,712,533; 8,768,472; 8,792,988; 9,327,125; 9,333,357; and 9,480,842. 1 The asserted patents are directed to high-frequency ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Nevro Corp Nevro Corp litigation history",
              "retrieved_at": "2025-01-06T21:06:53.765263+00:00",
              "published_date": null,
              "source_hash": "95ff0dd144246d9cb9936c6906458c71"
            },
            {
              "url": "",
              "title": "FOR THE DISTRICT OF DELAWARE C.A. No. BOSTON SCIENTIFIC CORP. and ...",
              "snippet": "2 Nevro Corp. v. Boston Scientific Corp., C.A. No. 3:16-cv-06830, D.I. 202-8 (N.D. Cal. ... Years of litigation between BSC and Nevro has revealed a continual pattern of BSC watching Nevro's innovations and copying them to maintain and advance BSC's competitiveness in the SCS market.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Nevro Corp Nevro Corp litigation history",
              "retrieved_at": "2025-01-06T21:06:53.765274+00:00",
              "published_date": null,
              "source_hash": "32aff49024ad0c359ffbbd92e73b747c"
            },
            {
              "url": "",
              "title": "Boston Scientific to pay Nevro $85 mln to end pain treatment patent ...",
              "snippet": "Medical-device maker Boston Scientific Corp has agreed to pay Nevro Corp $85 million to settle their patent dispute over spinal-stimulation technology, despite winning $20 million from Nevro at ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Nevro Corp Nevro Corp litigation history",
              "retrieved_at": "2025-01-06T21:06:53.765284+00:00",
              "published_date": null,
              "source_hash": "b8b26be1e9ad2a29151120ddd597be9e"
            },
            {
              "url": "",
              "title": "Spinal Cord Stim Company Nevro vs. Boston Scientific",
              "snippet": "October 2020 Wells Fargo Securities, LLC (Wells Fargo) provided an update to the ongoing patent litigation between Nevro Corp. and Boston Scientific Corporation indicating the potential for a speedy resolution. The litigation revolves around several of Nevro's patents related to its high-frequency spinal cord stimulation system.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Nevro Corp Nevro Corp litigation history",
              "retrieved_at": "2025-01-06T21:06:53.765295+00:00",
              "published_date": null,
              "source_hash": "a31b923e3b517d6575aff855000727b1"
            },
            {
              "url": "",
              "title": "Nevro Corp v. Bos. Sci. Corp. - Casetext",
              "snippet": "Socarras provides services related to the prosecution of Nevro's patents; is involved in patent enforcement; advises Nevro's executive team about IP portfolio management; and manages Nevro's IP litigation-related matters, which includes evaluating discovery, pleadings, and motions. Id. \u00b6\u00b6 4-5, 10-11. Moreover, Socarras \"evaluat[es] new third ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Nevro Corp Nevro Corp litigation history",
              "retrieved_at": "2025-01-06T21:06:53.765304+00:00",
              "published_date": null,
              "source_hash": "4b2e766663e4823011b0b8bb5fbf15df"
            },
            {
              "url": "",
              "title": "Nevro and Boston Scientific Settle Patent Litigation",
              "snippet": "The agreement between the parties puts an end to the existing litigation. Founded in 2006, Nevro is a global medical device company focused on developing solutions for chronic pain treatment. It initially launched itself into the implantable spinal cord stimulation market and came up with its 10 kHz Therapy.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Nevro Corp Nevro Corp litigation history",
              "retrieved_at": "2025-01-06T21:06:53.765317+00:00",
              "published_date": null,
              "source_hash": "0e5b7af9af21f07b570f21c928042562"
            },
            {
              "url": "",
              "title": "Nevro Corp. - Nevro Announces Agreement to Conclude Its Patent Lawsuit ...",
              "snippet": "Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that, in its patent litigation against Boston Scientific, the parties agreed to the dismissal of the patent case filed by Nevro in the Northern District of California relating to high frequency paresthesia-free SCS therapy. The ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Nevro Corp Nevro Corp litigation history",
              "retrieved_at": "2025-01-06T21:06:53.765327+00:00",
              "published_date": null,
              "source_hash": "25516066b20c26556f0b8f83ab32d728"
            },
            {
              "url": "",
              "title": "RBC Capital Remains a Hold on Nevro Corp (NVRO)",
              "snippet": "In a report released on December 17, Shagun Singh Chadha from RBC Capital maintained a Hold rating on Nevro Corp (NVRO - Research Report), with",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Nevro Corp Nevro Corp litigation history",
              "retrieved_at": "2025-01-06T21:06:57.329737+00:00",
              "published_date": "2024-12-19T10:31:00+00:00",
              "source_hash": "413c757a219c514e43cacecca6354d65"
            },
            {
              "url": "",
              "title": "J&J, Stryker among potential suitors for Nevro: Wolfe",
              "snippet": "Wolfe upgraded Nevro to Peer Perform from Underperform but removed its $14 price target. More on Johnson & Johnson, Nevro, etc. Nevro Corp. (NVRO) Q2 2024 Earnings Call Transcript",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Nevro Corp Nevro Corp litigation history",
              "retrieved_at": "2025-01-06T21:06:57.329820+00:00",
              "published_date": "2024-08-08T19:00:00+00:00",
              "source_hash": "9d4eeeb59340a33d02f8a01604ced8aa"
            },
            {
              "url": "",
              "title": "Nevro Corp's SWOT analysis: stock faces headwinds amid SCS market challenges",
              "snippet": "Nevro Corp (NYSE:NVRO), a medical device company specializing in spinal cord stimulation (SCS) technology for chronic pain treatment, finds itself navigating a challenging market landscape as it ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Nevro Corp Nevro Corp litigation history",
              "retrieved_at": "2025-01-06T21:06:57.329837+00:00",
              "published_date": "2024-12-03T04:50:00+00:00",
              "source_hash": "1bc2a3559b1e9b55896d4ca92291cdaa"
            },
            {
              "url": "",
              "title": " Nevro Corp. Corporate Governance Guidelines",
              "snippet": "US-DOCS\\106700042.3 CORP-00006 Rev-A NEVRO CORP. CORPORATE GOVERNANCE GUIDELINES (Adopted October 9, 2014; as Amended May 13, 2019, March 24, 2020 and March 25, 2021) ... compliance with, these Guidelines and consider such matters as they may deem appropriate at such ... of other major issues respecting, the appropriate auditing and accounting ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Nevro Corp Nevro Corp regulatory compliance issues",
              "retrieved_at": "2025-01-06T21:06:59.909218+00:00",
              "published_date": null,
              "source_hash": "75c8f67f2cd800f0449a76936a4fa7ed"
            },
            {
              "url": "",
              "title": "Nevro Corp. - Corporate Governance",
              "snippet": "At Nevro Corp., we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the 'unsubscribe' section below. If you experience any issues with this process, please contact us for further assistance.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Nevro Corp Nevro Corp regulatory compliance issues",
              "retrieved_at": "2025-01-06T21:06:59.909330+00:00",
              "published_date": null,
              "source_hash": "20f1d684a73eb95540d9a42fca2f709b"
            },
            {
              "url": "",
              "title": " Code of Business Conduct & Ethics - s28.q4cdn.com",
              "snippet": "Nevro's policies, and applicable laws apply specifically to their work on Nevro's behalf; \u2022 Create a safe environment in which team members feel comfortable discussing ethical or compliance questions, issues, or concerns; \u2022 Recognize and reward behaviors that model our core values, including by considering ethical and compliant",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Nevro Corp Nevro Corp regulatory compliance issues",
              "retrieved_at": "2025-01-06T21:06:59.909346+00:00",
              "published_date": null,
              "source_hash": "825a605f2ca2c65260c41eccd77417fa"
            },
            {
              "url": "",
              "title": "Understanding the Boston Scientific Spinal Cord Stimulator Lawsuit",
              "snippet": "These issues led to talks about a potential class action lawsuit. Patient reviews and documented complications caught legal attention quickly. ... 2.2 Regulatory compliance requirements; 2.3 Intellectual property rights in medical devices; ... Boston Scientific and Nevro Corporation's patent infringement litigation stands as a defining case ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Nevro Corp Nevro Corp regulatory compliance issues",
              "retrieved_at": "2025-01-06T21:06:59.909366+00:00",
              "published_date": null,
              "source_hash": "18c69f8726846de4897c72160f1859fc"
            },
            {
              "url": "",
              "title": " Report On Our Environmental, Social and Governance Responsibilities",
              "snippet": "Global Compliance 48 Nevro 2021 ESG Report Nevro.com 3. Nevro is the creator of HF10\u00ae, an innovative, evidence-based treatment for chronic pain. Headquartered in Redwood City, California, Nevro was established in 2006 with the simple ... corporate life to bring a higher level of clinical and scientific evidence to the treatment of chronic pain ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Nevro Corp Nevro Corp regulatory compliance issues",
              "retrieved_at": "2025-01-06T21:06:59.909381+00:00",
              "published_date": null,
              "source_hash": "a3632b151d6e2c93bdf0864f6700803b"
            },
            {
              "url": "",
              "title": "10-K - SEC.gov",
              "snippet": "UNITED STATES. SECURITIES AND EXCHANGE COMMISSION. Washington, D.C. 20549 FORM 10-K \u2612 Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2023. or \u2610 Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number: 001-36715 NEVRO CORP.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Nevro Corp Nevro Corp regulatory compliance issues",
              "retrieved_at": "2025-01-06T21:06:59.909393+00:00",
              "published_date": null,
              "source_hash": "8d6faec31548cae4618469910cc3ee7f"
            },
            {
              "url": "",
              "title": "Nevro Corp. - Nevro and Boston Scientific Announce the Settlement of ...",
              "snippet": "Nevro Corp. (NYSE: NVRO) and Boston Scientific Corp. (NYSE: BSX) announced today that they have reached a settlement in their ongoing intellectual property litigations that gives Boston Scientific the freedom to operate using the features and capabilities embodied in its current line of products for frequencies below 1,500 Hz, and gives Nevro the freedom to operate using the features and ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Nevro Corp Nevro Corp regulatory compliance issues",
              "retrieved_at": "2025-01-06T21:06:59.909404+00:00",
              "published_date": null,
              "source_hash": "e5fdeac0dfda876161e3e82d9110cf6a"
            },
            {
              "url": "",
              "title": "Nevro Corp. - EN - Corporate Governance",
              "snippet": "YOU ARE ABOUT TO EXIT FOR A WEBSITE INTENDED FOR THE RESIDENTS OF ANOTHER COUNTRY OR REGION. Please be aware that the website you have requested is intended for the residents of a particular country or region, as noted on that site.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Nevro Corp Nevro Corp regulatory compliance issues",
              "retrieved_at": "2025-01-06T21:06:59.909415+00:00",
              "published_date": null,
              "source_hash": "c27593a2c52e305dd1c915fd7af179ab"
            },
            {
              "url": "",
              "title": "Nevro Corp v. Bos. Sci. Corp. - Casetext",
              "snippet": "Read Nevro Corp v. Bos. Sci. Corp., Case No. 16-cv-06830-VC (MEJ), see flags on bad law, ... Factors to consider include \"the importance of the issues at stake in the action, the amount in controversy, the parties' relative access to relevant information, the parties' resources, the importance of the discovery in resolving the issues, and ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Nevro Corp Nevro Corp regulatory compliance issues",
              "retrieved_at": "2025-01-06T21:06:59.909424+00:00",
              "published_date": null,
              "source_hash": "85ff371d55bf044444b812235d958c13"
            },
            {
              "url": "",
              "title": "Nevro Corp.: Governance, Directors and Executives & Committees ...",
              "snippet": "Nevro Corp. is a global medical device company. The Company is focused on delivering solutions that continue to set the standard for enduring patient outcomes in chronic pain treatment. Its comprehensive HFX spinal cord stimulation 3 (SCS) platform includes the Senza SCS system and support services for the treatment of chronic pain of the trunk ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Nevro Corp Nevro Corp regulatory compliance issues",
              "retrieved_at": "2025-01-06T21:06:59.909444+00:00",
              "published_date": null,
              "source_hash": "1c352ac25fcd3a184decb31be4235321"
            },
            {
              "url": "",
              "title": "Nevro Corp. Reports Strong Q3 2024 Financial Performance",
              "snippet": "Nevro Corp ( (NVRO)) just unveiled an announcement ... including new market releases and regulatory approvals in Europe. Nevro continues to adjust its financial guidance, maintaining focus ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Nevro Corp Nevro Corp regulatory compliance issues",
              "retrieved_at": "2025-01-06T21:07:02.374632+00:00",
              "published_date": "2024-11-14T21:37:00+00:00",
              "source_hash": "90323e9bbf07d98d35eda43b0d145e75"
            },
            {
              "url": "",
              "title": "Where Nevro Stands With Analysts",
              "snippet": "Unveiling the Story Behind Nevro Nevro Corp is a medical device company. Its key product is the HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Nevro Corp Nevro Corp regulatory compliance issues",
              "retrieved_at": "2025-01-06T21:07:02.374713+00:00",
              "published_date": "2024-12-18T20:01:00+00:00",
              "source_hash": "7f0ea8af367192432e7e31e4eb756e23"
            },
            {
              "url": "",
              "title": "Nevro Stock Rises on Q3 Earnings Beat, Revenues Decrease Y/Y",
              "snippet": "Nevro Corp. NVRO reported a loss per share of 41 ... the United States in the fourth quarter of 2024. Nevro also received regulatory approval to sell its HFX iQ system in CE-marked countries ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Nevro Corp Nevro Corp regulatory compliance issues",
              "retrieved_at": "2025-01-06T21:07:02.374726+00:00",
              "published_date": "2024-11-12T18:24:00+00:00",
              "source_hash": "9f9dd572d36452912639c1926ecfb2f1"
            },
            {
              "url": "",
              "title": "Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08",
              "snippet": "REDWOOD CITY, Calif., Dec. 17, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Nevro Corp Nevro Corp regulatory compliance issues",
              "retrieved_at": "2025-01-06T21:07:02.374735+00:00",
              "published_date": "2024-12-17T00:00:00+00:00",
              "source_hash": "9df81dbad8a0ad19d0aac08e96841512"
            },
            {
              "url": "",
              "title": "State Street Corp Sells 241,495 Shares of Nevro Corp. (NYSE:NVRO)",
              "snippet": "State Street Corp trimmed its holdings in Nevro Corp. (NYSE:NVRO - Free Report) by 24.3% during the 3rd quarter, Holdings Channel.com reports. The fund owned 752,631 shares of the medical ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Nevro Corp Nevro Corp regulatory compliance issues",
              "retrieved_at": "2025-01-06T21:07:02.374744+00:00",
              "published_date": "2024-12-30T00:00:00+00:00",
              "source_hash": "60cc4eaec3bb2636769aedca5fe9eb32"
            },
            {
              "url": "",
              "title": " 1.5 Tesla and 3 Tesla Magnetic Resonance Imaging (MRI ... - Nevro HFX",
              "snippet": "NEVRO CORP. All questions or concerns about Nevro products should be forwarded to: Nevro Corp. 1800 Bridge Parkway . Redwood City, CA 94065 USA ... An item with demonstrated safety in the MR environment within defined conditions. ... A patient with this device can be safely scanned in an MR system meeting the following",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Nevro Corp Nevro Corp patient safety concerns",
              "retrieved_at": "2025-01-06T21:07:05.996150+00:00",
              "published_date": null,
              "source_hash": "0ba09cc18903173e167b04008cf4be23"
            },
            {
              "url": "",
              "title": "Nevro Corp. - EN - Safety",
              "snippet": "Important Safety Information 10 kHz Therapy and other available SCS frequencies and waveforms are delivered by Senza Spinal Cord Stimulation (SCS) systems. 1 Throughout this website all referenced SCS system components including the Implantable Pulse Generator (IPG), Leads, and Accessories are a part of the Senza System.",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Nevro Corp Nevro Corp patient safety concerns",
              "retrieved_at": "2025-01-06T21:07:05.996180+00:00",
              "published_date": null,
              "source_hash": "87ec66ccd500b6f70068e231ea9d8ba5"
            },
            {
              "url": "",
              "title": "Safety Information - Nevro HFX",
              "snippet": "For more than 10 years, the Nevro HFX Spinal Cord Stimulation* system has been a safe and effective approach to managing chronic pain. However, like any medical procedure, it's important to review all benefits, risks, safety information with your doctor.",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Nevro Corp Nevro Corp patient safety concerns",
              "retrieved_at": "2025-01-06T21:07:05.996189+00:00",
              "published_date": null,
              "source_hash": "6add60429f7515408fbb121bfb386b8f"
            },
            {
              "url": "",
              "title": " Patient Manual - Food and Drug Administration",
              "snippet": "NEVRO CORP. All questions or concerns about Nevro products should be forwarded to: Nevro Corp. 1800 Bridge Parkway Redwood City, CA 94065 USA Tel: +1.650.251.0005 Fax: +1.650.251.9415 info@nevro.com MDSS GMBH Australian Sponsor Emergo Australia Schiffgraben 41 Level 20, Tower II, Darling Park D-30175 Hannover, 201 Sussex Street, Sydney, NSW 2000",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Nevro Corp Nevro Corp patient safety concerns",
              "retrieved_at": "2025-01-06T21:07:05.996196+00:00",
              "published_date": null,
              "source_hash": "42700d069fbac422f84e179da43a4d67"
            },
            {
              "url": "",
              "title": " United States Court of Appeals for the Federal Circuit",
              "snippet": "NEVRO CORP. v. BOSTON SCIENTIFIC CORP. 5 . implanting a signal generator in the patient; electrically coupling the percutaneous lead to the signal generator; and . programming the signal generator to generate and deliver an electrical therapy signal to the spinal cord region, via the at least one electrode, wherein",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Nevro Corp Nevro Corp patient safety concerns",
              "retrieved_at": "2025-01-06T21:07:05.996202+00:00",
              "published_date": null,
              "source_hash": "8788fb345ccd048733fc60bf65934f4e"
            },
            {
              "url": "",
              "title": "Nevro Corp. - New Data Demonstrates Long-Term Improvements in Pain ...",
              "snippet": "Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced the publication of new data in the Journal of Pain Research demonstrating significant, durable pain relief and long-term and clinically meaningful reductions in hemoglobin A1c (HbA1c) and weight in study participants with painful ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Nevro Corp Nevro Corp patient safety concerns",
              "retrieved_at": "2025-01-06T21:07:05.996208+00:00",
              "published_date": null,
              "source_hash": "dfe697f95eb40fac263dce472782daf4"
            },
            {
              "url": "",
              "title": "Nevro Corp. - New Study Demonstrates Multiple Advantages of Nevro1 ...",
              "snippet": "Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced the publication of new data in Medical Devices: Evidence and Research , which demonstrate the superiority of the Nevro1\u2122 SI Joint Fusion System (\"Nevro1\"), a posterior integrated transfixation cage system offering enhanced ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Nevro Corp Nevro Corp patient safety concerns",
              "retrieved_at": "2025-01-06T21:07:05.996214+00:00",
              "published_date": null,
              "source_hash": "d49f3bfe20c3de0b1c133339356743c4"
            },
            {
              "url": "",
              "title": "Nevro Corp. - Nevro Announces Completion of Patient Enrollment in ...",
              "snippet": "Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain conditions, today announced that it has completed patient enrollment in its prospective, multicenter Randomized Controlled Trial (RCT) for the treatment of chronic pain for patients who suffer from Painful Diabetic Neuropathy (PDN). \"This is an ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Nevro Corp Nevro Corp patient safety concerns",
              "retrieved_at": "2025-01-06T21:07:05.996222+00:00",
              "published_date": null,
              "source_hash": "3aff1f02a0e915a4187e7d3171620c13"
            },
            {
              "url": "",
              "title": "Indirect Comparison of 10 kHz Spinal Cord Stimulation (SCS) versus ...",
              "snippet": "Stimulation-treated subjects in the Petersen study received 10 kHz SCS, a modality that provides pain relief without paresthesia (Nevro Corp. ). In the remaining 2 RCTs, participants assigned to LF-SCS received a study-specific manufacturer device that induced continuous paresthesia to mask the sensation of pain (Medtronic [ 39 ] and St. Jude ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Nevro Corp Nevro Corp patient safety concerns",
              "retrieved_at": "2025-01-06T21:07:05.996229+00:00",
              "published_date": null,
              "source_hash": "24bdca659695220f319cb1ad5f5695bd"
            },
            {
              "url": "",
              "title": "Understanding the Boston Scientific Spinal Cord Stimulator Lawsuit",
              "snippet": "Patient safety protocols. Patient safety measures have improved based on lessons from the boston scientific spinal cord stimulator problems. The FDA has spotted several critical areas that need better monitoring. Data shows 428 reported deaths and thousands of injuries linked to spinal cord stimulators. Recent regulatory changes require:",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Nevro Corp Nevro Corp patient safety concerns",
              "retrieved_at": "2025-01-06T21:07:05.996234+00:00",
              "published_date": null,
              "source_hash": "c02305e6ff07092b3e8841b6fcac8976"
            },
            {
              "url": "",
              "title": "Nevro Corp's Market Cap Challenges: Impairment Risks and Investor Concerns",
              "snippet": "Nevro Corp (NVRO) has disclosed a new risk, in the Accounting & Financial Operations category. Nevro Corp faces a significant financial risk due to potential declines in its market capitalization ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Nevro Corp Nevro Corp patient safety concerns",
              "retrieved_at": "2025-01-06T21:07:08.265085+00:00",
              "published_date": "2024-11-13T00:02:00+00:00",
              "source_hash": "00342185b8fd00acadd7fb09362ddd9e"
            },
            {
              "url": "",
              "title": "Hold Rating on Nevro Corp Amid Cost-Cutting Concerns and Upcoming Product Launches",
              "snippet": "Morgan Stanley analyst Kallum Titchmarsh maintained a Hold rating on Nevro Corp (NVRO - Research Report ... have raised concerns about how they might affect the company's revenue-generating ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Nevro Corp Nevro Corp patient safety concerns",
              "retrieved_at": "2025-01-06T21:07:08.265123+00:00",
              "published_date": "2024-11-12T05:09:00+00:00",
              "source_hash": "0bba14d0b4e66459fa0a43a893c87958"
            },
            {
              "url": "",
              "title": "What Analysts Are Saying About Nevro Stock",
              "snippet": "Nevro Corp is a medical device company ... a clinician laptop programmer, a patient remote control, and a mobile charger. The company generates the majority of its revenue in the United States.",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Nevro Corp Nevro Corp patient safety concerns",
              "retrieved_at": "2025-01-06T21:07:08.265134+00:00",
              "published_date": "2024-12-02T11:00:00+00:00",
              "source_hash": "a9c907bbb19b26d7e701660285d36b44"
            },
            {
              "url": "",
              "title": "Nevro Corp. (NYSE:NVRO) Q3 2024 Earnings Call Transcript",
              "snippet": "Nevro Corp. (NYSE:NVRO) Q3 2024 Earnings Call Transcript November 11, 2024 Nevro Corp. beats earnings expectations. Reported EPS is $-0.51, expectations were $-0.81. Operator: Good afternoon.",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Nevro Corp Nevro Corp patient safety concerns",
              "retrieved_at": "2025-01-06T21:07:08.265142+00:00",
              "published_date": "2024-12-10T23:30:00+00:00",
              "source_hash": "8a1c76df5c98023204278c86bd5448dc"
            },
            {
              "url": "",
              "title": "Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08",
              "snippet": "Dec. 17, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical ... solutions that continue to set the standard for enduring patient outcomes in chronic pain treatment.",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Nevro Corp Nevro Corp patient safety concerns",
              "retrieved_at": "2025-01-06T21:07:08.265150+00:00",
              "published_date": "2024-12-17T00:00:00+00:00",
              "source_hash": "ae8f785ad6b358c0852ba9a39577d0de"
            }
          ],
          "queries": [
            {
              "category": "financial_legal",
              "query": "Nevro Corp litigation history",
              "rationale": "Investigate past and ongoing legal disputes, including product liability and intellectual property cases",
              "priority": 1
            },
            {
              "category": "financial_legal",
              "query": "Nevro Corp regulatory compliance issues",
              "rationale": "Examine challenges with FDA, CE, and other regulatory approvals, including delays or rejections",
              "priority": 2
            },
            {
              "category": "ethical_social",
              "query": "Nevro Corp patient safety concerns",
              "rationale": "Assess reports or controversies related to adverse effects or safety issues with Nevro's products",
              "priority": 3
            }
          ]
        },
        "categorization": {
          "product_issues": [],
          "conduct_issues": [],
          "tags": [],
          "patterns": {}
        }
      },
      "metadata": {
        "analysis_timestamp": "2025-01-06T14:07:23.164314",
        "data_confidence": 80,
        "pattern_confidence": null
      }
    }
  ]
}